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ABSTRACT
Despite the efficacy of a number of first-line
treatments, most patients with advanced-stage non-
small cell lung cancer (NSCLC) experience disease
progression that warrants further treatment. In this
review, we examine the role of novel active agents for
patients who progress after first-line therapy and who
are not candidates for targeted therapies. More
therapeutic options are needed for the management of
patients with NSCLC after failure of first-line
chemotherapy. A PubMed search was performed for
articles from January 2012 to May 2015 using the
keywords NSCLC, antiangiogenic, immunotherapy,
second-line, novel therapies and English language
articles only. Relevant papers were reviewed; papers
outside that period were considered on a case-by-case
basis. A search of oncology congresses was performed
to identify relevant abstracts over this period. In recent
years, antiangiogenic agents and immune checkpoint
inhibitors have been added to our armamentarium to
treat patients with advanced NSCLC who have
progressed on first-line chemotherapy. These include
nintedanib, a triple angiokinase inhibitor; ramucirumab,
a vascular endothelial growth factor receptor-2
antibody; and nivolumab, pembrolizumab and
atezolizumab, just three of a growing list of antibodies
targeting the programmed death receptor-1 (PD-1)/PD
ligand-1 pathway. Predictive and prognostic factors in
NSCLC treatment will help to optimise treatment with
these novel agents. The approval of new treatments for
patients with NSCLC after the failure of first-line
chemotherapy has increased options after a decade of
few advances, and holds promise for future evolution
of the management of NSCLC.
INTRODUCTION
Lung cancer incidence, particularly adeno-
carcinoma,1 is increasing globally and the
disease remains the most commonly
diagnosed cancer. The majority of patients
(85%) are diagnosed with non-small cell
lung cancer (NSCLC)2 and, within this popu-
lation, adenocarcinoma and squamous cell
carcinoma are the two major histological sub-
types, accounting for ∼45% and 25% of
cases, respectively, with large variations
according to geographical location.3 4 Up to
45% of patients with advanced NSCLC
experience disease progression during first-
line chemotherapy,5–7 and all patients with
initial disease control will eventually experi-
ence progression and require subsequent
therapy.
Until 2014, the available agents for the
second-line treatment of advanced NSCLC
without driver mutations included docetaxel
(Taxotere; Sanofi-Aventis, Bridgewater, USA),
pemetrexed (Alimta; Eli Lilly, Indianapolis,
USA) (non-squamous patients only) and erloti-
nib (Tarceva, Genentech/OSI Pharmaceuticals/
Roche).8 9 In this review, we will examine the
role of recently approved novel therapies in
the management of patients with NSCLC,
with a particular focus on antiangiogenic
agents and immune checkpoint inhibitors fol-
lowing first-line chemotherapy.
TUMOUR ANGIOGENESIS: A TREATMENT
TARGET
Angiogenesis is widely accepted as a funda-
mental process for the growth of primary
tumours and their subsequent metastases,10
involving multiple receptors and their asso-
ciated pathways (figure 1).
Vascular endothelial growth factor (VEGF)
has a prominent role in angiogenesis,
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mediating its effects via endothelial cells; consequently,
the VEGF/VEGF receptor (VEGFR) pathway has been a
very attractive therapeutic target.10 Proangiogenic path-
ways have substantial redundancy, allowing tumours to
bypass the inhibition of a single pathway and to adapt to
the presence of antiangiogenic agents.11 Acquired re-
sistance involves interaction between cells and the
tumour microenvironment, and uses various different
proangiogenic pathways (including fibroblast growth
factor (FGF), platelet-derived growth factor (PDGF)
and other signalling pathways) to recruit vascula-
ture.11 12 The tumour microenvironment—which
includes both the malignant transformed cells, and
also stromal, immune and endothelial cells—also plays
a role in tumour progression.13 It is postulated that
non-malignant cells, including immune cells that infil-
trate a tumour, acquire tumour-promoting functions,
including encouraging the creation of new blood
vessels and facilitating rapid expansion and progression
towards malignancy.
The two main types of antiangiogenic agents that have
been investigated in NSCLC are monoclonal antibodies
and small-molecule tyrosine kinase inhibitors (TKIs),
both of which target specific angiogenic receptors and
pathways (table 1).
Bevacizumab (Avastin; Genentech/Roche, Basel,
Switzerland), a humanised monoclonal antibody that
binds to VEGF-A, provided proof-of-principle for antian-
giogenic therapy in NSCLC in combination with first-
line platinum-based chemotherapy and is approved in
patients with advanced non-squamous NSCLC.14
Subsequent extensive investigation of other antiangio-
genic agents in advanced NSCLC did not result in regu-
latory approvals in the first-line or maintenance
setting.11 However, promising results were reported in
previously treated patients with NSCLC.
ANTIANGIOGENIC AGENTS
Over the past decade, numerous clinical trials involving
novel agents in patients with NSCLC who progressed on
first-line therapy reported modest improvements in
progression-free survival (PFS) but no significant
improvements in overall survival (OS). These include
vandetanib (ZODIAC, ZEAL and ZEST trials),15–17 afli-
bercept (VITAL),18 bevacizumab (BeTa)19 and sunitinib
(SUN1087)20 21 as monotherapy, or in combination with
chemotherapy (docetaxel or pemetrexed) or erlotinib.
In 2014, two antiangiogenic agents were approved for
patients with advanced NSCLC after first-line chemo-
therapy. The results of the LUME-Lung 1 trial
(NCT00805194, study 1199.13) first led to European
Union (EU) approval of nintedanib (Vargatef;
Boehringer Ingelheim, Ingelheim, Germany), in com-
bination with docetaxel, for the treatment of patients
with locally advanced, metastatic or locally recurrent
NSCLC of adenocarcinoma histology after first-line
chemotherapy.22 Subsequently, results of the REVEL
Figure 1 Overview of important signalling pathways in
angiogenesis and antiangiogenic agents. Reprinted by
permission from Macmillan Publishers: Llovet et al53
copyright 2015. FGFR, fibroblast growth factor receptor;
PDGFR, platelet-derived growth factor receptor; VEGF,
vascular endothelial growth factor; VEGFR, vascular
endothelial growth factor receptor.
Table 1 Targeted agents influencing angiogenesis
evaluated in NSCLC
Agent Description Target
Bevacizumab MAb VEGF-A
Ramucirumab MAb VEGFR-2
Anlotinib TKI VEGFR-2–3
Apatinib TKI VEGFR-2
Axitinib TKI VEGFR-1–3, PDGFR,
c-kit
Cediranib TKI VEGF-1–3
Fruquintinib TKI VEGFR-1–3
Lenvatinib TKI VEGFR-1–3,
PDGFR-α, FGFR-1–4,
RET and c-kit
Motesanib TKI VEGFR-1–3, PDGFR,
kit, RET
Nintedanib TKI VEGFR-1–3, FGFR-1–
3, PDGFR-α/β
Pazopanib TKI VEGFR, PDGFR and
c-kit
Sorafenib TKI VEGFR-1–3, RET,
PDGFR, Flt-3, c-kit
Sunitinib TKI VEGFR-1/2,
PDGFR-α/β, Flt-3 and
c-kit
Vandetanib TKI VEGFR, EGFR, RET
Aflibercept Decoy receptor All VEGF-A isoforms,
VEGF-B, PIGF
Endostar Recombinant
human
endostatin
VEGF-induced
phosphorylation of
VEGFR-2, FGF-2
EGFR, epidermal growth factor receptor; FGF, fibroblast growth
factor; FGFR, fibroblast growth factor receptor; MAb, monoclonal
antibody; NSCLC, non-small cell lung cancer; PDGFR,
platelet-derived growth factor receptor; PlGF, placental growth
factor; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial
growth factor; VEGFR, vascular endothelial growth factor receptor.
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trial (NCT01168973, study 13852) led to the US and EU
approvals of ramucirumab (Cyramza; Eli Lilly,
Indianapolis, USA) in combination with docetaxel for
patients with metastatic NSCLC with disease progression
on or after platinum-based chemotherapy.22 23
Nintedanib
Nintedanib is an oral, triple angiokinase inhibitor that
inhibits VEGFR-1–3, FGF receptors 1–3 and PDGF
receptor-α and PDGF receptor-β.24 Nintedanib also inhi-
bits FLT3 and the Src kinase family.
Two phase III trials assessed the efficacy and safety of
nintedanib.25 26 Both studies were similar in design:
multinational, randomised, double-blind, placebo-
controlled trials conducted in Eastern Cooperative
Oncology Group performance score (ECOG PS) 0–1
patients with histologically or cytologically confirmed
stage IIIB/IV or recurrent NSCLC after one previous
platinum-based chemotherapy.25 26
In LUME-Lung 1, 1314 patients were randomised to
receive nintedanib (200 mg two times a day, n=655) or
placebo (n=659) on days 2–21 in combination with doce-
taxel (75 mg/m2) on day 1, every 3 weeks. The two
major histologies were adenocarcinoma (n=658) and
squamous cell carcinoma (n=555). The study met its
primary end point of PFS by independent central review,
with nintedanib plus docetaxel showing significant
improvement in median PFS versus placebo plus doce-
taxel (3.4 vs 2.7 months, HR 0.79, p=0.002) independent
of histology.25 The key secondary end point, OS, was
tested in a prespecified stepwise order, maintaining
adequate power: first, in patients with adenocarcinoma
histology who progressed within 9 months after the start
of first-line therapy; then in all adenocarcinoma patients;
and then in the overall population. A significant
increase in median OS (10.9 vs 7.9 months, HR 0.75,
95% CI 0.60 to 0.92, p=0.007) was observed in the ninte-
danib arm versus the placebo arm in patients with
adenocarcinoma histology who progressed within
9 months after the start of first-line therapy (figure 2A).
In the adenocarcinoma population, median OS was
longer than 1 year in the nintedanib arm and signifi-
cantly longer than in the placebo arm (12.6 vs
10.3 months, HR 0.83, 95% CI 0.70 to 0.99, p=0.036)
(figure 2B). In the overall population, the 1-month
increase in median OS in the nintedanib arm was not
statistically significant (HR 0.94, 95% CI 0.83 to 1.05,
p=0.272) (figure 2C). In an exploratory analysis of che-
morefractory adenocarcinoma patients with disease pro-
gression as best response to first-line therapy, treatment
with nintedanib also significantly increased survival
(median OS 9.8 vs 6.3 months, HR 0.62, 95% CI 0.41 to
0.94 p=0.025). Further exploratory analysis reported
decreased tumour burden and decelerated tumour
growth over time in the nintedanib arm compared with
the placebo arm in adenocarcinoma patients, including
patients with the poorest prognosis.27
In the overall population, there were higher inci-
dences in the nintedanib arm than in the placebo arm
of diarrhoea (all grades: 42% vs 22%; grade ≥3: 7% vs
3%), liver-enzyme elevations (aspartate aminotransfer-
ase, all grades: 23% vs 7%; grade ≥3: 3% vs 1%; alanine
aminotransferase, all grades: 29% vs 8%; grade ≥3: 8%
vs 1%) that were reversible in the majority of patients,
nausea (all grades: 24% vs 18%; grade ≥3: 1% vs 1%)
and decreased appetite (all grades: 22% vs 16%; grade
≥3: 1% vs 1%).25 These adverse events (AEs, Common
Terminology Criteria for Adverse Events (CTCAE) V.3.0)
were manageable with supportive treatment or dose
reduction. The incidence of AEs associated with VEGF
inhibition was generally low; bleeding events and hyper-
tension were slightly higher with nintedanib than with
placebo. Similarly, the incidence of AEs associated with
docetaxel (such as peripheral neuropathy and mucosi-
tis) was slightly higher in the nintedanib arm than in
the placebo arm. A similar AE profile was observed in
the adenocarcinoma population.
In LUME-Lung 2, patients with non-squamous NSCLC
were randomised to either nintedanib (200 mg two
times a day, n=353) or placebo (n=360) on days 2–21
plus pemetrexed (500 mg/m2) on day 1, every 3 weeks.
An independent data monitoring committee (DMC)
conducted a preplanned futility analysis of investigator-
assessed PFS and recommended that the study be halted
prematurely. Subsequent analysis demonstrated a signifi-
cant improvement in centrally reviewed PFS favouring
the nintedanib arm over the placebo arm (median PFS
4.4 vs 3.6 months, HR 0.83, 95% CI 0.70 to 0.99,
p=0.040).26 A retrospective analysis of the futility calcula-
tions indicated that the predefined threshold for futility
was only crossed at the time of the futility analysis for
investigator-assessed PFS, but not for centrally reviewed
PFS at any point during the study, suggesting that the
single time point for preplanned futility analysis was
inadequate. Nintedanib plus pemetrexed had a manage-
able safety profile with no new or unexpected findings.
Ramucirumab
Ramucirumab is an intravenously administered mono-
clonal antibody that specifically binds to the extracellu-
lar domain of VEGFR-2.28 The multicentre,
double-blind, randomised phase III REVEL study
assessed the efficacy and safety of docetaxel (75 mg/m2)
plus ramucirumab (10 mg/kg, n=627) or placebo
(n=625) every 3 weeks in ECOG PS 0–1 patients with
stage IV NSCLC who progressed during or after first-line
platinum-based chemotherapy.28 29 The study met its
primary end point of OS, with a longer survival reported
for ramucirumab plus docetaxel compared with doce-
taxel plus placebo (10.5 vs 9.1 months, HR 0.86, 95% CI
0.75 to 0.98, p=0.023) (figure 3). Median PFS, a second-
ary end point, was also higher in the ramucirumab arm
versus the placebo arm (4.5 vs 3.0 months, HR 0.76,
95% CI 0.68 to 0.86; p<0.0001).
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Figure 2 Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of
<9 months (A), all patients with adenocarcinoma (B) and the total population (C) from LUME-Lung 1. Patients without
documented death were censored at the date of last contact when the patient was known to be alive. Adapted from Reck
et al.25 Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer
(LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. 143–155, Copyright (2014), with permission from Elsevier.
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REVEL was not powered for subgroup analysis accord-
ing to histology; however, longer median OS was
observed with ramucirumab plus docetaxel than with
placebo plus docetaxel in patients with non-squamous
NSCLC (n=912; 11.1 months vs 9.7 months; HR 0.83,
95% CI 0.71 to 0.97, p=0.02),28 including patients with
adenocarcinoma histology (n=725; 11.2 months vs
9.8 months; HR 0.83, 95% CI 0.69 to 0.99; p value not
reported).29 In the squamous population, a numerically
longer median OS in the ramucirumab arm did not
reach statistical significance (n=328; 9.5 months vs
8.2 months; HR 0.88, 0.69 to 1.13; p=0.32).28 In a uni-
variate exploratory analysis, patients with time since start
of prior therapy of <9 months had a longer OS in the
ramucirumab arm versus the placebo arm (HR 0.75,
95% CI 0.64 to 0.88).28
In REVEL, the most frequently observed AEs (CTCAE
V.4.0) in the ramucirumab arm were similar to those
observed in the placebo arm and included fatigue (all
grades: 55% vs 49%; grade ≥3: 14% vs 10%), decreased
appetite (all grades: 29% vs 25%; grade ≥3: 2% vs 1%),
diarrhoea (all grades: 32% vs 27%; grade ≥3: 5% vs
3%), nausea (all grades: 27% vs 27%; grade ≥3: 1% vs
1%) and alopecia (all grades: 26% vs 25%; grade ≥3:
NA).28 AEs observed more frequently in the ramuciru-
mab arm (≥10% difference between treatment arms)
were neutropenia (55% vs 45%) and stomatitis (23% vs
13%). Overall, the toxicities observed with ramucirumab
were manageable with dose adjustments or supportive
care. AEs associated with VEGF inhibition that were
higher in the ramucirumab arm included bleeding
(29% vs 15%) with most events related to epistaxis (19%
vs 6%), and hypertension (11% vs 5%) with more than
half of events at grade ≥3 (6% vs 2%).28 The frequency
of grade ≥3 pulmonary haemorrhage was comparable
between the treatment arms.
IMMUNE CHECKPOINT INHIBITORS
Results with programmed death receptor-1 (PD-1) inhi-
bitors and PD ligand-1 (PD-L1) inhibitors were encour-
aging in early clinical trials, leading to several large,
randomised phase III trials in previously treated patients
with NSCLC.30 PD-1 is expressed on several immune
cells, including T cells, B cells and natural killer cells,
whereas PD-L1 is expressed on tumour cells, as well as a
range of immune effector cells. The PD-1/PD-L1 inter-
action has a strong immunosuppressive effect in downre-
gulating T-cell function, and blockade of the PD-1/
PD-L1 pathway using antagonistic monoclonal anti-
bodies has been shown to increase the number and
functionality of tumour-specific T cells (figure 4).31
Nivolumab
Nivolumab is a fully human immunoglobulin (Ig) G4
antibody that disrupts PD-1-mediated signalling and has
the potential to restore antitumour immunity.32 Phase
III trials for nivolumab versus docetaxel in patients with
squamous (CheckMate-017, NCT01642004) and non-
squamous (CheckMate-057, NCT01673867) histology
after the failure of platinum-based doublet chemother-
apy were stopped early following planned interim ana-
lyses and a DMC assessment that concluded that both
studies met their primary end point, demonstrating
superior OS in patients receiving nivolumab when com-
pared to the control arm.32 33 Nivolumab (Opdivo;
Bristol-Myers Squibb, New York, USA) has received US
and EU approval for the treatment of locally advanced
or metastatic NSCLC with progression on or after
chemotherapy.34
In the CheckMate-017 study (n=272), patients with
stage IIIB/IV, squamous NSCLC and ECOG 0–1 were
randomised to receive nivolumab (3 mg/kg every
2 weeks) or docetaxel (75 mg/m2 every 3 weeks);
Figure 3 Kaplan-Meier curves for overall survival in the REVEL trial (intent-to-treat population). Reprinted from Garon et al.28
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer
after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. 665–673,
Copyright (2014), with permission from Elsevier.
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patients were required to submit pretreatment (archival
or recent) tumour-tissue specimen for retrospective bio-
marker analyses.33 Treatment with nivolumab improved
median OS by 3.2 months from 6.0 months for doce-
taxel to 9.2 months for nivolumab in patients with squa-
mous NSCLC (HR 0.59, 95% CI 0.44 to 0.79, p<0.001)
(figure 5). PFS also significantly improved (HR 0.62,
95% CI 0.47 to 0.81, p<0.001). OS and PFS were similar
among the subgroups of patients with differing levels of
PD-L1 expression.
The similarly designed CheckMate-057 study (n=582)
also demonstrated a superior OS (median OS
12.2 months vs 9.4 months, HR 0.73, 96% CI 0.59 to
0.89, p=0.002) with nivolumab in patients with non-
squamous NSCLC (figure 6).32 There was no significant
improvement in PFS (HR 0.92, 95% CI 0.77 to 1.11,
p=0.39). In terms of PD-L1 expression, median OS was
higher with nivolumab than with docetaxel in patients
with ≥1% PD-L1 expression (17.7 months vs 9.0 months,
HR 0.58, 95% CI 0.43 to 0.79) but similar in patients
Figure 5 Kaplan-Meier curves for overall survival in the CheckMate-017 trial (intent-to-treat population). Reprinted from
Brahmer et al.33
Figure 4 Overview of checkpoint blockade activating antitumour immunity and checkpoint immune inhibitors in development
in NSCLC. Reprinted by permission from Macmillan Publishers : Wolchok et al.54 MHC, major histocompatibility complex; PD-1,
programmed death receptor-1; PD-L1, programmed death receptor ligand-1.
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with <1% PD-L1 expression (10.5 months vs
10.1 months, HR 0.87, 95% CI 0.63 to 1.19). Nivolumab
appeared to be more effective in patients with a longer
time from completion of the most recent regimen to
randomisation, with an HR for OS of 0.46 (95% CI 0.27
to 0.79) in patients with more than 6 months from com-
pletion of most recent regimen to randomisation versus
0.85 (95% CI 0.67 to 1.08) in patients with <3 months to
randomisation. The most frequently observed any-grade
AEs were similar in the two treatment arms (98% vs
99%). Any grade treatment-related AEs were lower with
nivolumab than with docetaxel (69% vs 88%) as were
grade ≥3 AEs (10% vs 54%). Frequent all-causality AEs
(CTCAE V.4.0) with nivolumab included fatigue
(all grades: 32% vs 38%; grade 3–4: 3% vs 7%),
decreased appetite (all grades: 29% vs 22%; grade 3–4:
2% vs 1%), cough (all grades: 26% vs 23%; grade 3–4:
<1% vs 0), constipation (all grades: 23% vs 17%; grade
3–4: 1% vs 1%), dyspnoea (all grades: 23% vs 24%;
grade 3–4: 5% vs 4%), nausea (all grades: 22% vs 30%;
grade 3–4: 2% vs 1%) and asthenia (all grades: 21% vs
23%; grade 3–4: 3% vs 4%). Safety profiles were similar
between the subgroups of patients with PD-L1 expres-
sion of <1% and ≥1%. Immune-modulating agents were
administered to resolve AEs such as rash and pruritus.
Safety profiles were comparable in the CheckMate-057
and CheckMate-017 studies.32 33
Pembrolizumab
Pembrolizumab is a monoclonal IgG4 anti-PD-1 antibody
that disrupts the engagement of PD-1 with its ligand.35 The
KEYNOTE-001 phase I study (NCT01295827) enrolled 495
patients of whom 101 were treatment-naïve and 394 previ-
ously treated for advanced or metastatic NSCLC and with
ECOG status 0–1. Overall, 401 (81%) patients had non-
squamous histology, 85 (17%) had squamous NSCLC and
9 (2%) had adenosquamous or unknown histology.
Treatment with pembrolizumab (2 mg/kg or 10 mg/kg
every 3 weeks or 10 mg/kg every 2 weeks) demonstrated
antitumour activity (objective response rate (ORR) 19.4%,
mean response duration: 12.5 months) and an acceptable
side-effect profile in the overall population.35 Biomarker
analysis was performed, with results being reported as the
percentage of neoplastic cells showing PD-L1 staining
(tumour proportion score (TPS)). The biomarker-
evaluable population included 73 patients with TPS ≥50%
and 131 patients with TPS <50%. ORR was significantly
higher (43.9% vs 14.1%; p<0.001) for previously treated
patients with TPS ≥50% (n=57) than those with TPS <50%
(n=99). Median PFS among patients with a TPS ≥50% was
6.1 months for previously treated patients. At a follow-up
analysis with a data cut-off 6 months after the primary data
cut-off, among 124 previously treated patients with PD-L1
TPS ≥50%, median PFS was 5.8 months and median OS
was 14.0 months (HR not reported).36
Based on results from the KEYNOTE-001 study, pem-
brolizumab (Keytruda; Merck & Co, Kenilworth, USA)
was granted accelerated approval in the USA for the
treatment of patients with metastatic NSCLC whose
tumours express PD-L1, as determined by a Food and
Drug Administration (FDA)-approved test and who have
disease progression on or after platinum-containing
chemotherapy.37 The PD-L1 immunohistochemistry
(IHC) 22C3 pharmDx test is designed to detect PD-L1
expression, with tumour samples considered to be
PD-L1-positive if ≥50% of viable cells exhibit membrane
staining. Based on this cut-off, KEYNOTE-001 reported
the estimated prevalence of PD-L1-positive patients as
22.7% of the previously treated patient population.35
In the KEYNOTE-010 phase II/III study
(NCT01905657), previously treated PD-L1-positive (TPS
≥1%) patients with advanced NSCLC were randomised in
a 1:1:1 ratio to receive either pembrolizumab 2 mg/kg
every 3 weeks (n=344), pembrolizumab 10 mg/kg every
3 weeks (n=346) or docetaxel 75 mg/m2 every 3 weeks
(n=343).38 Primary end points were OS and PFS in the
total population and in patients with TPS ≥50%. A total of
724 patients (70.1%) had non-squamous disease, 222
Figure 6 Kaplan-Meier curves for overall survival in the CheckMate-057 trial (intent-to-treat population). Reprinted from
Borghaei et al.32
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patients (21.5%) had squamous disease and 87 patients
(8.4%) had other/unknown histology. In patients with
PD-L1 TPS ≥50%, median OS was 14.9 months for the
2 mg/kg group (HR vs docetaxel 0.54, 95% CI 0.38 to
0.77, p=0.0002), 17.3 months for the 10 mg/kg group (HR
vs docetaxel 0.50, 95% CI 0.36 to 0.70, p<0.0001) and
8.2 months for the docetaxel group (figure 7A). In the
total population, median OS was 10.4 months (HR vs doce-
taxel 0.71, 95% CI 0.58 to 0.88, p=0.0008) for patients
treated with pembrolizumab 2 mg/kg, 12.7 months (HR vs
docetaxel 0.61, 95% CI 0.49 to 0.75, p<0.0001) for the
pembrolizumab 10 mg/kg arm and 8.5 months for the
docetaxel arm (figure 7B). Patients with adenocarcinoma
(n=708) had greater OS benefit with pembrolizumab
compared with docetaxel treatment (HR 0.63, 95% CI 0.50
to 0.79). PFS improvement was not statistically significant
for either pembrolizumab arm versus docetaxel.
Treatment-related AEs (CTCAE V.4.0) at any grade and at
grade ≥3 were more frequent with docetaxel with either
dose of pembrolizumab (all grades: pembrolizumab 2 mg/
kg 63%, pembrolizumab 10 mg/kg 66%, docetaxel 81%;
grade ≥3: pembrolizumab 2 mg/kg 13%, pembrolizumab
10 mg/kg 16%, docetaxel 35%). Treatment-related AEs
that were frequent with pembrolizumab included
decreased appetite (all grades: 14% vs 10% vs 16%; grade
≥3: 1% vs <1% vs 1%), fatigue (all grades: 14% vs 14% vs
25%; grade ≥3: 1% vs 2% vs 4%), nausea (all grades: 11%
vs 9% vs 15%; grade ≥3: <1% vs 1% vs <1%) and rash (all
grades: 9% vs 13% vs 5%; grade ≥3: <1% vs <1% vs 0).
Immune-mediated AEs occurred at manageable rates,
although three (<1%) of the 682 pembrolizumab-treated
patients died of pneumonitis. Safety profiles were compar-
able in the KEYNOTE-001 and KEYNOTE-010 studies.35 38
Other checkpoint inhibitors
In this rapidly advancing area of clinical research other
PD-L1 checkpoint inhibitors are being intensively investi-
gated including atezolizumab (MPDL3280A, Roche),
Figure 7 Kaplan-Meier curves for overall survival in patients with PD-L1 tumour proportion score of ≥50% (A) and all patients
from KEYNOTE-010 (B). Adapted from Herbst et al.38 Pembrolizumab versus docetaxel for previously treated, PD-L1-positive,
advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. 1540–1550, Copyright (2015), with
permission from Elsevier.
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durvalumab (MEDI4736, AstraZeneca) and avelumab
(MSB0010718C, Merck KGaA/Pfizer). Of these investi-
gational agents atezolizumab has recently received
Breakthrough Therapy Designation from the FDA,
based on results in PD-L1-positive NSCLC.39 Results
from an open-label, phase 2 randomised controlled trial,
in patients with advanced NSCLC who progressed on
postplatinum chemotherapy showed that atezolizumab
significantly improved survival compared with docetaxel
(12.6 months, 95% CI 9.7 to 16.4 vs 9.7 months 95% CI
8.6 to 12.0; HR=0.73, 95% CI 0.53 to 0.99; p=0.04).
Increasing improvement in OS was also noted in patients
with higher levels of PD-L1 expression treated with ate-
zolizumab compared with docetaxel.40 Although the
clinical programme is not as advanced as atezolizumab,
treatment with durvalumab in combination with the
cytotoxic T-lymphocyte-associated protein 4 inhibitor tre-
melimumab in patients with locally advanced or meta-
static NSCLC showed evidence of clinical activity in
patients with PD-L1-positive tumours and in those with
PD-L1-negative tumours. The response in PD-L1 nega-
tive tumours represents a potential therapeutic option
for a group of patients who have not benefited as much
from the use of other checkpoint inhibitors in trials
undertaken to date.41 Other studies are being under-
taken as summarised in table 2 and in general check-
point inhibitors have also shown encouraging trends
across other solid tumour types, in phase I develop-
ment.42–46
PREDICTIVE AND PROGNOSTIC FACTORS
Approaches to identify biomarkers/clinical markers
include genotyping and simpler assessment of tissue
samples, such as pathological and molecular tumour fea-
tures, grade and pathology of the tumour, as well as
plasma/serum markers. Characterising tumours accord-
ing to histological subtype and genetic composition has
resulted in significant progress in the identification of
response to certain drugs, for example, the epidermal
growth factor receptor (EGFR)-activating mutations.47
Antiangiogenic agents
Despite progress in the identification of predictive bio-
markers in patients with differing tumour mutational
status, none have been identified for those who receive
antiangiogenic agents.48 49 A major challenge in identi-
fying potential biomarkers to antiangiogenic therapy is
the complex nature of the angiogenic signalling process,
which is characterised by multiple overlapping path-
ways.50 The activation of compensatory bypass angio-
genic pathways after initial treatment response is a
significant roadblock as it results in the development of
resistance.50 Consequently, there remains an urgent
need for biomarkers to angiogenesis inhibitors in the
treatment of cancer, including NSCLC.51
Analyses of the LUME-Lung 1 study have been con-
ducted to identify a prognostic and/or predictive factor
for the OS improvement observed in adenocarcinoma
patients who received nintedanib plus docetaxel after
first-line therapy.52 The analysis also used data from
patients in the LUME-Lung 2 trial. These analyses suggest
that: (1) time since the start of first-line therapy was a
prognostic and predictive clinical biomarker for the treat-
ment effect of nintedanib, combined with either doce-
taxel or pemetrexed, for patients with advanced
non-squamous NSCLC, progressing after platinum-based
chemotherapy; and (2) a treatment benefit was evident in
those non-squamous patients with a particularly poor
prognosis who progressed during or shortly after first-line
treatment. Results from the REVEL study also confirm
time since the start of first-line therapy as a potential clin-
ical marker for ramucirumab.28
PD-1/PD-L1 inhibition
PD-L1 is upregulated in many cancer types and contri-
butes to malignancy by inhibiting T-cell activation,
Table 2 Overview of phase III trials of antiprogrammed death receptor-1 (PD-1)/programmed death receptor ligand-1
(PD-L1) inhibitors completed or ongoing in previously treated patients with advanced NSCLC
Agent Target Trial name, identifier Design
Nivolumab PD-1 CheckMate-057,
NCT01673867
Nivolumab in previously treated patients with NSCLC vs
docetaxel alone in patients with non-squamous histology
CheckMate-017,
NCT01642004
Nivolumab in previously treated patients with NSCLC vs
docetaxel alone in patients with squamous histology
Pembrolizumab PD-1 KEYNOTE-010,
NCT01905657
Pembrolizumab vs docetaxel in patients with NSCLC who have
experienced disease progression after platinum-containing
therapy
Atezolizumab
(MPDL3280A)
PD-L1 OAK, NCT02008227 MPDL3280A vs docetaxel in patients with locally advanced or
metastatic NSCLC who have failed platinum therapy
Durvalumab
(MEDI4736)
PD-L1 ARCTIC, NCT02352948 MEDI4736, given as monotherapy or in combination with
tremelimumab, determined by PD-L1 expression vs standard of
care in patients with locally advanced or metastatic NSCLC
Avelumab
(MSB0010718C)
PD-L1 JAVELIN Lung 200,
NCT02395172
MSB0010718C vs docetaxel in patients with PD-L1-positive,
advanced NSCLC after failure of a platinum-containing doublet
NSCLC, non-small cell lung cancer; PD-1, programmed death receptor-1; PD-L1, programmed death receptor ligand-1.
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limiting tumour cell killing by the immune system;
PD-L1 expression assessed by IHC is being investigated
as a marker for many anti-PD-1/PD-L1 agents.22 23
PD-L1 positivity may indicate that an immune-active
tumour may be sensitive to anti-PD-1 or PD-L1 therapy
because of a correlation with PD-L1 expression and
poor prognosis in cancers, including lung adenocarcin-
oma.22 However, the predictive and/or prognostic uses
of PD-L1 expression remain unclear. Several studies have
shown improved responses to anti-PD-1 or anti-PD-L1
therapy in ‘PD-L1-positive’ cases; however, most studies
also report significant response rates (3–30%) in
PD-L1-negative tumours. There is variable definition of
PD-L1 positivity in tumours, ranging from ≥1% to ≥50%
of cells assessed showing PD-L1 expression. PD-L1 has
dynamic expression, which could, together with hetero-
geneous expression, confound the determination of a
positive or negative assay result. Despite the different
approaches to PD-L1 assessment for each of the drugs in
this class, an association between expression and
response has been reasonably consistent. The presence
of response in patients deemed to be PD-L1-negative has
called into question the validity of this biomarker.
Undoubtedly, the PD-L1 biomarker does not show the
predictive performance of EGFR mutation or ALK
fusion for targeted therapy with TKIs. However, the
biology of the immune system, the action of the therapy
and the nature of the IHC test all mean that lesser pre-
dictive power is inevitable.
To date, concordance between the different IHC anti-
bodies used in the trials has not been reported. The
assays available vary in their ability to detect PD-L1, and
although some assays consider tumour cell expression,
others also score immune-cell PD-L1 expression.22 Low
staining thresholds, such as 1% or 5%, reflect the fact
that PD-L1 expression is heterogeneous; however, they
carry a greater risk that scoring will be inconsistent and
an inaccurate representation of a patient’s tumour
burden.23 Small sample sizes in these studies may also
play a role.
The variability in PD-L1 testing used and validated in
trials poses serious challenges for pathologists in deliver-
ing this biomarker test, assuming it will be requested. An
international effort for a standardised approach could
enable the use of PD-L1 expression as a reliable bio-
marker for anti-PD-1/PD-L1 therapy.23
Plasma and circulating tumour cells have also been
proposed as alternative forms of non-invasive, blood-
based biomarker analysis.22 Plasma PD-L1 protein could
provide a method for monitoring PD-1/PD-L1
interaction in NSCLC.
FUTURE DIRECTIONS
Defining ‘clinically meaningful’ benefit is complex and
a balance is needed between ‘objective’ end points
(which have value in benchmarking) versus ‘subjective’
end points, including patient-oriented factors such as
symptom relief, quality of life and toxicity reduction.
Median OS remains an important outcome for bench-
marking of clinical practice, but other measures should
be considered, including survival HR, 1-year and 2-year
survival rates, and patient-related factors.
It is important to continue the search for clinical and
molecular prognostic and predictive factors. Patient
selection through the use of biomarkers is important in
choosing the correct treatment option. A shorter time
since start of first-line therapy is a potential clinical
marker for the antiangiogenic agents, considering the
lower OS benefit from immunotherapy in patients with
shorter time since completion of their most recent
chemotherapy regimen. Collection of tumour and blood
samples is essential in future studies to help identify bio-
markers in order to select patients who will benefit the
most. In addition, a standardised approach to measuring
PD-L1 expression is needed to be a consistent biomarker
for anti-PD-1/PD-L1 therapy.
CONCLUSIONS
In the past few years, new treatment options have
become available for patients with NSCLC whose disease
has progressed after or during first-line chemotherapy.
This has come after a decade of only few advances in
this setting, and holds promise for the future evolution
of the management of NSCLC.
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